Overview

Lonafarnib With Ritonavir in HDV (LOWR-2)

Status:
Completed

Trial end date:
2017-06-15

Target enrollment:

Participant gender:

Summary

An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2).

Phase:

Phase 2

Details

Lead Sponsor:

Eiger BioPharmaceuticals

Collaborator:

Ankara University

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Lonafarnib
Peginterferon alfa-2a
Ritonavir